Published in Neurobiol Aging on May 11, 2006
Effect of Indomethacin on the Progression of Alzheimer's Disease | NCT00432081
Microglia in neurodegenerative disease. Nat Rev Neurol (2010) 5.83
Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov (2010) 3.48
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12
Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry (2008) 2.66
Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest (2007) 2.48
Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol (2008) 2.46
Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener (2009) 2.23
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation (2008) 2.03
Genetics of Alzheimer's disease: recent advances. Genome Med (2009) 1.95
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci (2009) 1.84
TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry (2013) 1.74
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation (2012) 1.57
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iran J Pharm Res (2011) 1.42
Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain (2008) 1.42
Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain (2013) 1.40
APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol (2009) 1.37
Effects of neuroinflammation on the regenerative capacity of brain stem cells. J Neurochem (2011) 1.27
NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci (2008) 1.27
Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol (2008) 1.23
A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep (2012) 1.22
Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol (2009) 1.20
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis (2010) 1.19
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J Neurochem (2007) 1.16
Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY) (2009) 1.13
Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. Biochimie (2010) 1.13
Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement (2009) 1.13
Inflammation as a potential mediator for the association between periodontal disease and Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 1.12
Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis (2013) 1.08
Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta (2010) 1.07
Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci (2014) 1.06
Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder? Am J Cardiovasc Dis (2013) 1.05
The Toll-->NFkappaB signaling pathway mediates the neuropathological effects of the human Alzheimer's Abeta42 polypeptide in Drosophila. PLoS One (2008) 1.05
Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot Essent Fatty Acids (2008) 1.05
APOE genotype alters glial activation and loss of synaptic markers in mice. Glia (2012) 1.04
Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation (2012) 1.03
Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp Neurol (2009) 1.02
Microglia in Alzheimer's Disease: It's All About Context. Int J Alzheimers Dis (2012) 1.02
The dynamics of monocytes and microglia in Alzheimer's disease. Alzheimers Res Ther (2015) 1.02
Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol (2009) 1.02
DHA may prevent age-related dementia. J Nutr (2010) 1.02
Chronic IL-1β-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer's disease without inducing overt neurodegeneration. J Neuroimmune Pharmacol (2011) 1.02
Microglial derived tumor necrosis factor-α drives Alzheimer's disease-related neuronal cell cycle events. Neurobiol Dis (2013) 1.02
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease. J Neural Transm (Vienna) (2011) 1.01
No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One (2008) 1.01
Gene expression of cyclooxygenase-1 and Ca(2+)-independent phospholipase A(2) is altered in rat hippocampus during normal aging. Brain Res Bull (2007) 1.00
Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. Anal Biochem (2007) 0.98
Proteasome-caspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells. J Neurochem (2009) 0.98
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. J Neural Transm (Vienna) (2012) 0.97
Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain (2015) 0.96
Resolution of inflammation is altered in Alzheimer's disease. Alzheimers Dement (2014) 0.95
Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 0.95
Elevated serum C-reactive protein relates to increased cerebral myoinositol levels in middle-aged adults. Cardiovasc Psychiatry Neurol (2012) 0.94
Cyclooxygenase-1 mediates prostaglandin E(2) elevation and contextual memory impairment in a model of sustained hippocampal interleukin-1beta expression. J Neurochem (2010) 0.93
Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis (2010) 0.93
Implications of glial nitric oxide in neurodegenerative diseases. Front Cell Neurosci (2015) 0.93
Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J (2013) 0.93
Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where. Future Neurol (2012) 0.93
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem (2012) 0.91
Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J Neuroinflammation (2012) 0.91
Vinpocetine as a potent antiinflammatory agent. Proc Natl Acad Sci U S A (2010) 0.91
Dietary n-6 polyunsaturated fatty acid deprivation increases docosahexaenoic acid metabolism in rat brain. J Neurochem (2012) 0.90
Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol Neurodegener (2012) 0.90
Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci (2014) 0.90
Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma. Curr Med Chem (2009) 0.90
Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid β. J Neuroinflammation (2011) 0.89
Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J Neurochem (2010) 0.89
Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Mol Neurodegener (2007) 0.88
Oxidative stress is related to the deleterious effects of heme oxygenase-1 in an in vivo neuroinflammatory rat model. Oxid Med Cell Longev (2013) 0.88
Estrogen or estrogen receptor agonist inhibits lipopolysaccharide induced microglial activation and death. Neurochem Res (2010) 0.88
Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly. Biomed Res Int (2014) 0.87
Function and comorbidities of apolipoprotein e in Alzheimer's disease. Int J Alzheimers Dis (2011) 0.87
Ccr2-64i and Ccr5 Δ32 Polymorphisms in Patients with Late-Onset Alzheimer's disease; A Study from Iran (Ccr2-64i And Ccr5 Δ32 Polymorphisms in Alzheimer's disease). Iran J Basic Med Sci (2012) 0.87
Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J Alzheimers Dis (2011) 0.87
Dealing with misfolded proteins: examining the neuroprotective role of molecular chaperones in neurodegeneration. Molecules (2010) 0.86
Relationship between tau pathology and neuroinflammation in Alzheimer's disease. Mt Sinai J Med (2010) 0.86
Alzheimer's disease: pathological mechanisms and recent insights. Curr Neuropharmacol (2011) 0.86
R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer's disease. Brain Res (2013) 0.84
Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models. Brain (2015) 0.84
DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain. Am J Pathol (2009) 0.84
Microsomal prostaglandin E synthase-2: cellular distribution and expression in Alzheimer's disease. Exp Neurol (2009) 0.84
Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance. Acta Pharmacol Sin (2009) 0.83
Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. J Lipid Res (2015) 0.82
Drug development for Alzheimer's disease: recent progress. Exp Neurobiol (2010) 0.82
Sex-dependent effect of cyclooxygenase-2 inhibition on mouse spatial memory. Behav Brain Res (2009) 0.80
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive? Brain Res (2014) 0.80
Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease. Exp Mol Pathol (2013) 0.80
Leucine-rich α2-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex. PLoS One (2013) 0.80
The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging. Brain Res (2014) 0.80
Progress and perspectives on the role of RPE cell inflammatory responses in the development of age-related macular degeneration. J Inflamm Res (2008) 0.80
Lack of Association between Tumor Necrosis Factor-alpha -308 G/A Polymorphism and Risk of Developing Late-Onset Alzheimer's Disease in an Iranian Population. Avicenna J Med Biotechnol (2009) 0.79
Peripheral inflammatory markers in amnestic mild cognitive impairment. Int J Geriatr Psychiatry (2013) 0.79
Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin. Aging Dis (2010) 0.79
Glimepiride reduces CD14 expression and cytokine secretion from macrophages. J Neuroinflammation (2014) 0.79
Glial reactions in Parkinson's disease. Mov Disord (2008) 2.62
Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord (2004) 2.41
Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci (2004) 2.11
Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol (2002) 1.59
Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis (2006) 1.58
LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol (2006) 1.46
Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol (2007) 1.38
Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging (2006) 1.24
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol (2013) 1.23
Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun (2009) 1.20
Mechanisms of GABA release from human astrocytes. Glia (2011) 0.96
Targeting microglia for the treatment of Alzheimer's disease. Expert Opin Ther Targets (2014) 0.94
History of innate immunity in neurodegenerative disorders. Front Pharmacol (2011) 0.93
Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol (2008) 0.91
The possible role of complement activation in Alzheimer disease. Trends Mol Med (2002) 0.90
Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease. Neurosci Lett (2002) 0.89
Innate immunity, local inflammation, and degenerative disease. Sci Aging Knowledge Environ (2002) 0.89
Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex. Neurobiol Aging (2012) 0.88
Aurin tricarboxylic acid self-protects by inhibiting aberrant complement activation at the C3 convertase and C9 binding stages. Neurobiol Aging (2012) 0.86
Interleukin 1alpha and interleukin 6 protect human neuronal SH-SY5Y cells from oxidative damage. Neurosci Lett (2004) 0.86
The ALS/PDC syndrome of Guam: potential biomarkers for an enigmatic disorder. Prog Neurobiol (2011) 0.86
The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. Exp Neurol (2008) 0.86
Optineurin in Huntington's disease intranuclear inclusions. Neurosci Lett (2011) 0.84
GAD65, GAD67, and GABAT immunostaining in human brain and apparent GAD65 loss in Alzheimer's disease. J Alzheimers Dis (2013) 0.81
Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques. Exp Gerontol (2002) 0.79
Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathol (2007) 0.78
Interferon-γ-induced neurotoxicity of human astrocytes. CNS Neurol Disord Drug Targets (2015) 0.75
A Method for Diagnosing Alzheimer's Disease Based on Salivary Amyloid-β Protein 42 Levels. J Alzheimers Dis (2016) 0.75